With promising early clinical data in psoriasis, psoriatic arthritis, and ankylosing spondylitis, dual inhibition of IL-17A and IL-17F with bimekizumab offers a new therapeutic approach for the treatment of patients with immune-mediated inflammatory diseases. This evidence concerns the gene IL17F and psoriatic arthritis.